Lupin

Lupin Manufacturing Solutions (LMS), a global CRDMO and subsidiary of global pharma major Lupin Limited (Lupin), today announced a…

Global pharma major Lupin has entered into a Licensing and Supply Agreement with Zydus Lifesciences, an innovation-led…

For India’s biopharma sector, 2025 stood out as an inflection point. The approval of 146 recombinant biosimilar therapeutic…

While we agree that “what got us here (an affordable generics powerhouse) will not get us there (a leader in pharma innovation)”,…

Company scores 91 out of 100; included in Sustainability Yearbook 2026 for third consecutive year

Company initiates US launch following ANDA approval for bioequivalent to Briviact

Following positive CHMP opinion, Lupin to commercialise RanluspecTM in EU through Sandoz partnership

Launch follows FDA approval for ANDA

Lupin announced the launch of Dasatinib tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following…

Lupin announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and…